12:00 AM
 | 
Mar 15, 1999
 |  BC Week In Review  |  Company News  |  Deals

BTG, LeukoSite deal

LKST received an exclusive license to BTG's anti-CD3 humanized aglycosylated antibody to...

Read the full 40 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >